A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Recruiting now · Phase 1/Phase 2

Conditions studied: NSCLC (Non-small Cell Lung Cancer), Solid Tumor

In brief

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

Key facts

Study ID

NCT06616766

Run by

Yuhan Corporation

People needed

161

Starts

2024-10-02

Expected to finish

2028-07-29

Last updated by the study team

2025-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG performance status 0 or 1
• Estimated life expectancy of at least 3 months
• Patients who have progressed on or after all available standard therapies or for whom standard treatment is inappropriate
• Mandatory provision of archived or fresh tumor tissue in quantity sufficient to allow for retrospective confirmation of HER2 or EGFR mutation
• A patient with a history of brain metastases must have had all lesions treated
• Adequate organ function defined as all of the following:
• Adequate bone marrow function (within 1 week prior to first administration): Neutrophils≥1.5 x10*9 cells/L (Criteria must be met without the use of Granulocyte-Colony Stimulating Factor (G-CSF) within last week prior to testing.); platelet count≥75 x10*9 cells/L; Hb ≥9g/dL (Criteria must be met without packed red blood cell (pRBC) transfusion within last week prior to testing.)
• Adequate hepatic function: Serum bilirubin≤1.5 x upper limit of normal (ULN), and serum transaminase (either aspartate transaminase (AST) or alanine transaminase (ALT)) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases (within 1 week prior to first administration)
• Adequate renal function: Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) > 60 mL/min per 1.73 m*2 according to the site's calculation method.
• [Dose Escalation part only]
• Histologically or cytologically confirmed diagnosis of advanced, and/or metastatic non-hematologic malignancy
• Documented HER2 or EGFR mutation (HER2 mutation or EGFR exon 20 insertion, HER2 amplification or overexpression)
• [Dose Expansion part only]
• Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC HER2 exon 20 insertion (Cohort 1)

You may not qualify if…

• Patient with symptomatic or progressive brain metastases
• Known or suspected leptomeningeal disease (LMD)
• Uncontrolled spinal cord compression
• History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
• History of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
• Medical, psychiatric, cognitive or other conditions that compromise the patients ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study
• Any severe concurrent disease or condition (includes active infections, cardiac arrhythmia) that in the judgment of the Investigator would make study participation inappropriate for the patient
• History of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
• History of a second primary cancer with the exception of
• curatively treated non-melanomatous skin cancer,
• curatively treated cervical or breast carcinoma in situ, or
• other malignancy with no known active disease present and no treatment administered during the last 2 years
• Infection with human immunodeficiency virus (HIV) or prior hepatitis B or active chronic hepatitis B or active hepatitis C
• Major surgery within 4 weeks prior to the first dose of study treatment

Where it is running

• Next Oncology Virginia — Fairfax, Virginia, United States (enrolling)
• Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea (enrolling)
• The Catholic Univ. of Korea St. Vincent's Hospital — Suwon, Gyeonggi-do, South Korea (enrolling)
• Chungbuk National University Hospital — Cheongju-si, North Chungcheong, South Korea (enrolling)
• Seoul National University Hospital — Seoul, South Korea (enrolling)
• Severance Hospital, Yonsei University — Seoul, South Korea (enrolling)
• Samsung Medical Center — Seoul, South Korea (enrolling)
• Asan Medical Center, University of Ulsan — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.